Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Launched by MILTENYI BIOMEDICINE GMBH · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is a long-term follow-up study for patients who have been treated with Miltenyi CAR T cell therapy for various types of cancer, including melanoma and different forms of leukemia. The main goal of the study is to see how safe and effective this treatment remains over an extended period of time. If you or a loved one received Miltenyi CAR T cell therapy at least 12 months ago and are interested in participating, you may be eligible for this study. There are no specific exclusions, so if you’ve given consent to join, you can take part in this follow-up.

Participants in this trial will be asked about their health and any side effects they may have experienced since their treatment. This is an important step in understanding how the therapy works over time and helps researchers improve future treatments. The study is currently recruiting, and anyone interested should reach out to learn more about joining and what it entails. Your experiences could provide valuable insights into the long-term effects of this innovative therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
• • Patient has provided informed consent prior to enrollment.
• Exclusion Criteria:
• • No exclusion criteria